The Institute for Clinical and Economic Review (ICER) released its revised value assessment framework, which included a number of changes reflected in NPC's extensive public comments, but NPC remains concerned about several key provisions that ICER has not addressed.

Patients who have the same condition sometimes pay different out-of-pocket costs for their medications, but when is this differential more appropriate? Our webinar addressed these questions and identified some of the ethical, legal and economic issues with variable copays based on NPC research. 

A new white paper highlights survey findings from payers and providers on what types of evidence are most important to them when it comes to making population coverage decisions for formularies and care pathways.